IN156469B - - Google Patents

Info

Publication number
IN156469B
IN156469B IN564/CAL/82A IN564CA1982A IN156469B IN 156469 B IN156469 B IN 156469B IN 564CA1982 A IN564CA1982 A IN 564CA1982A IN 156469 B IN156469 B IN 156469B
Authority
IN
India
Application number
IN564/CAL/82A
Other languages
English (en)
Inventor
Julien Pierre Verheyden
John Charles Martin
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23017790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN156469(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Inc filed Critical Syntex Inc
Priority to IN746/MAS/84A priority Critical patent/IN160603B/en
Priority to IN748/MAS/84A priority patent/IN160605B/en
Priority to IN747/MAS/84A priority patent/IN160604B/en
Publication of IN156469B publication Critical patent/IN156469B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IN564/CAL/82A 1981-05-21 1982-05-20 IN156469B (en:Method)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IN746/MAS/84A IN160603B (en:Method) 1981-05-21 1984-10-01
IN748/MAS/84A IN160605B (en:Method) 1981-05-21 1984-10-01
IN747/MAS/84A IN160604B (en:Method) 1981-05-21 1984-10-01

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06267210 US4355032B2 (en) 1981-05-21 1981-05-21 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent

Publications (1)

Publication Number Publication Date
IN156469B true IN156469B (en:Method) 1985-08-10

Family

ID=23017790

Family Applications (1)

Application Number Title Priority Date Filing Date
IN564/CAL/82A IN156469B (en:Method) 1981-05-21 1982-05-20

Country Status (33)

Country Link
US (1) US4355032B2 (en:Method)
EP (1) EP0066208B1 (en:Method)
JP (2) JPS57203086A (en:Method)
KR (1) KR890004663B1 (en:Method)
AR (1) AR244227A1 (en:Method)
AT (1) ATE15899T1 (en:Method)
AU (1) AU572086B2 (en:Method)
BR (1) BR8202931A (en:Method)
CA (3) CA1305139C (en:Method)
CS (4) CS235042B2 (en:Method)
DD (2) DD213218A5 (en:Method)
DE (1) DE3266644D1 (en:Method)
DK (2) DK150304C (en:Method)
ES (7) ES512414A0 (en:Method)
FI (1) FI73682C (en:Method)
GR (1) GR76459B (en:Method)
HK (1) HK67088A (en:Method)
HU (2) HU186514B (en:Method)
IE (1) IE53731B1 (en:Method)
IL (1) IL65836A (en:Method)
IN (1) IN156469B (en:Method)
LU (1) LU88334I2 (en:Method)
MY (1) MY8700793A (en:Method)
NL (2) NL930022I1 (en:Method)
NO (2) NO161740C (en:Method)
NZ (1) NZ200691A (en:Method)
PH (1) PH17975A (en:Method)
PL (4) PL136332B1 (en:Method)
PT (1) PT74934B (en:Method)
RO (2) RO84860B (en:Method)
SG (1) SG81687G (en:Method)
SU (1) SU1176841A3 (en:Method)
ZA (1) ZA823532B (en:Method)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US5157120A (en) * 1980-09-16 1992-10-20 Syntex (U.S.A.) Inc. Guanine derivatives
US4508898A (en) * 1980-09-16 1985-04-02 Ogilvie Kelvin K Antiviral triazine compounds
US4423050A (en) * 1981-05-21 1983-12-27 Syntex (U.S.A.) Inc. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent
US4507305A (en) * 1981-05-21 1985-03-26 Syntex (U.S.A.) Inc. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent
FI76086C (fi) * 1981-08-11 1988-09-09 Wellcome Found Foerfarande foer framstaellning av antivirala purinderivat.
NZ201662A (en) * 1981-08-26 1986-07-11 Merck & Co Inc 9-(1,3-(and 2,3)-dihydroxy-1-(and 2)-propoxy-methyl)guanine derivatives and methods for their preparation
IE830186L (en) * 1982-02-01 1983-08-01 Syntex Inc Purines
US5250535A (en) * 1982-02-01 1993-10-05 Syntex Inc. Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US4609662A (en) * 1982-10-14 1986-09-02 Burroughs Wellcome Co. Method for using purine derivatives
US4462986A (en) * 1982-11-04 1984-07-31 Ens Bio Logicals, Inc. Synergistic anti-herpes compositions
US4814335A (en) * 1982-12-30 1989-03-21 Biomeasure, Incorporated Antiviral compounds
US4461757A (en) * 1983-02-23 1984-07-24 Ens Bio Logicals Inc. Dimethylaminomethylenated anti-herpes compounds
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
US4880820A (en) * 1983-06-24 1989-11-14 Merck & Co., Inc. Guanine derivatives
GB8320308D0 (en) * 1983-07-28 1983-09-01 Wellcome Found Antiviral combinations
EP0138683A3 (en) * 1983-09-30 1988-01-20 Merck & Co. Inc. Purine derivatives, their application in anti-viral compositions
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
US4806642A (en) * 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
US4621140A (en) * 1984-02-23 1986-11-04 Syntex (U.S.A.) Inc. Process for preparing 2,6-substituted-9-(1,3-dihydroxy-2-propoxymethyl)-purines and certain derivatives
US4579849A (en) * 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
EP0190123A1 (en) * 1984-07-20 1986-08-13 GAUNTT, Charles, O. Immunoregulatory and anti-viral compound
CA1330797C (en) * 1984-12-12 1994-07-19 David J. Morgans, Jr. Alkoxy methyl ether and alkoxy methyl ester derivatives
SE8406538D0 (sv) 1984-12-21 1984-12-21 Astra Laekemedel Ab Novel derivatives of purine
US4642346A (en) * 1985-06-24 1987-02-10 Syntex (U.S.A.) Inc. Anhydrous crystalline 9-(1,3-dihydroxy-2-propoxymethyl)guanine
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
CA2005815C (en) * 1988-12-19 1999-08-03 Wellcome Foundation Limited (The) Antiviral acyclic nucleoside derivatives
US5068119A (en) * 1990-09-28 1991-11-26 Nabisco Brands, Inc. Acid-hydrolyzable ester derivatives as low calorie fat mimetics
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DK0705264T3 (da) * 1993-06-23 1999-10-18 Merrell Pharma Inc Carbo-acyliske nukleosidderivater som antivirale og antineoplastiske midler
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5565565A (en) * 1994-08-04 1996-10-15 Syntex (U.S.A.) Inc. Preparation of N-9 substituted guanine compounds
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
US5840763A (en) * 1994-12-12 1998-11-24 Smithkline Beecham Plc Treatment of a latent infection of herpes viruses
DE19536164A1 (de) * 1995-09-28 1997-04-03 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 9-[(2-Hyroxyethoxy)methyl]guanin (Acyclovir)
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US6040446A (en) 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IN179493B (en:Method) * 1996-02-22 1997-10-11 Lupin Laboraties Ltd
EP0976751A1 (en) * 1996-04-09 2000-02-02 Lupin Laboratories Limited A process for the isomerisation of an N-7 isomer into an N-9 isomer useful in the synthesis of acyclic nucleosides
US5852208A (en) * 1996-08-30 1998-12-22 Dixie Chemical Company, Inc. Method of producing compounds containing acyloxyalkoxy groups from alcohols
CN1091445C (zh) * 1999-12-29 2002-09-25 湖北省医药工业研究院 抗病毒药物中间体、它们的制备及应用
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20060189565A1 (en) * 2002-10-22 2006-08-24 Mathur Rajeev S Pharmaceutical compositions of ganciclovir
EP1565470A2 (en) * 2002-10-31 2005-08-24 Ranbaxy Laboratories Limited Process for the preparation of ganciclovir
WO2004048380A1 (en) * 2002-11-22 2004-06-10 Ranbaxy Laboratories Limited Process for the synthesis of ganciclovir
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
ITMI20031202A1 (it) * 2003-06-13 2004-12-14 Lyogen Ltd Forma di cristallina del ganciclovir
CN1860120A (zh) * 2003-08-28 2006-11-08 兰贝克赛实验室有限公司 无定形盐酸缬更昔洛韦
JP4746866B2 (ja) * 2004-11-19 2011-08-10 Ｔｃｍ株式会社 キャリッジ用ガタ抑制装置
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TW201026715A (en) * 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP6104504B2 (ja) * 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
CN101851239B (zh) * 2009-04-03 2012-11-28 上海益威实业有限公司 一种更昔洛韦的回收方法
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
WO2012154698A2 (en) * 2011-05-06 2012-11-15 Mckenna Charles E Method to improve antiviral activity of nucleotide analogue drugs
CN102627643B (zh) * 2012-04-10 2014-01-08 常州康丽制药有限公司 更昔洛韦的精制方法
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9505775B2 (en) * 2012-11-03 2016-11-29 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CN103059023B (zh) * 2012-12-31 2015-09-30 浙江车头制药股份有限公司 一种制备更昔洛韦晶型ⅱ的方法
US9486530B1 (en) 2013-08-30 2016-11-08 Exela Pharma Sciences, LLC Ganciclovir compositions and related methods
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113476413B (zh) * 2021-08-09 2022-06-28 海南海灵化学制药有限公司 一种注射用更昔洛韦钠冻干粉的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4060616A (en) * 1976-03-01 1977-11-29 Burroughs Wellcome Co. Purine derivatives with repeating unit
US4221910A (en) * 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
AU7938482A (en) * 1980-12-22 1982-07-20 Astra Lakemedel Aktiebolag Novel derivatives of guanine
FI76086C (fi) * 1981-08-11 1988-09-09 Wellcome Found Foerfarande foer framstaellning av antivirala purinderivat.

Also Published As

Publication number Publication date
ES8606869A1 (es) 1986-05-16
FI73682B (fi) 1987-07-31
NL930022I1 (nl) 1993-05-03
ES8505681A1 (es) 1985-06-16
JPH046195B2 (en:Method) 1992-02-05
NL930139I1 (nl) 1993-11-01
AU8389282A (en) 1982-11-25
EP0066208A1 (en) 1982-12-08
DK150304C (da) 1988-01-04
PL242100A1 (en) 1984-04-24
JPH0529399B2 (en:Method) 1993-04-30
ZA823532B (en) 1983-03-30
RO87387A (ro) 1985-08-31
CS235043B2 (en) 1985-04-16
RO84860A (ro) 1984-09-29
ES8404355A1 (es) 1984-05-01
US4355032B1 (en:Method) 1983-06-14
JPS57203086A (en) 1982-12-13
NZ200691A (en) 1986-11-12
HU188000B (en) 1986-03-28
DE3266644D1 (en) 1985-11-07
PL136637B1 (en) 1986-03-31
PL242101A1 (en) 1984-07-16
CS235044B2 (en) 1985-04-16
DD203052A5 (de) 1983-10-12
ES512414A0 (es) 1984-05-01
ES8601204A1 (es) 1985-11-16
ES520849A0 (es) 1984-11-01
IL65836A (en) 1991-04-15
DK504183A (da) 1983-11-03
CS235042B2 (en) 1985-04-16
SG81687G (en) 1989-07-07
SU1176841A3 (ru) 1985-08-30
PL136332B1 (en) 1986-02-28
ES8507549A1 (es) 1985-09-16
PT74934B (en) 1984-05-08
NL930139I2 (nl) 1997-07-01
CS235018B2 (en) 1985-04-16
MY8700793A (en) 1987-12-31
ATE15899T1 (de) 1985-10-15
FI821794A0 (fi) 1982-05-20
US4355032B2 (en) 1990-10-30
CA1305141C (en) 1992-07-14
PL246770A1 (en) 1984-08-27
DK150304B (da) 1987-02-02
EP0066208B1 (en) 1985-10-02
KR830010112A (ko) 1983-12-26
DK504183D0 (da) 1983-11-03
ES529384A0 (es) 1987-01-01
IL65836A0 (en) 1982-08-31
BR8202931A (pt) 1983-05-03
AR244227A1 (es) 1993-10-29
ES533821A0 (es) 1985-06-16
ES8500276A1 (es) 1984-11-01
PL136004B1 (en) 1986-01-31
PL136579B1 (en) 1986-02-28
JPH04217983A (ja) 1992-08-07
FI73682C (fi) 1987-11-09
DD213218A5 (de) 1984-09-05
DK227782A (da) 1982-11-22
CA1305139C (en) 1992-07-14
GR76459B (en:Method) 1984-08-10
HU186514B (en) 1985-08-28
US4355032A (en) 1982-10-19
NO821676L (no) 1982-11-22
PH17975A (en) 1985-02-22
CA1305140C (en) 1992-07-14
KR890004663B1 (ko) 1989-11-24
IE53731B1 (en) 1989-02-01
PT74934A (en) 1982-06-01
ES524899A0 (es) 1985-09-16
LU88334I2 (fr) 1994-09-09
RO84860B (ro) 1984-10-30
NO161740B (no) 1989-06-12
RO87387B (ro) 1985-08-31
HK67088A (en) 1988-09-02
ES529383A0 (es) 1986-05-16
NO161740C (no) 1989-09-20
DK149001C (da) 1988-11-28
PL236521A1 (en) 1984-01-02
DK149001B (da) 1985-12-16
ES8701496A1 (es) 1987-01-01
NO1994005I1 (no) 1994-07-29
ES524900A0 (es) 1985-11-16
IE821210L (en) 1982-11-21
AU572086B2 (en) 1988-05-05

Similar Documents

Publication Publication Date Title
US4355032B1 (en:Method)
FR2504072B1 (en:Method)
FR2498570B3 (en:Method)
CH655549B (en:Method)
FR2501380B1 (en:Method)
DE3138365C2 (en:Method)
FR2503282B1 (en:Method)
FR2503831B1 (en:Method)
DE3231609C2 (en:Method)
FR2504484B1 (en:Method)
FR2503816B1 (en:Method)
FR2500710B1 (en:Method)
CH655567B (en:Method)
FR2498269B1 (en:Method)
FR2498392B1 (en:Method)
FR2500803B3 (en:Method)
FR2498266B3 (en:Method)
FR2497909B1 (en:Method)
FR2500782B1 (en:Method)
DE3231658A1 (en:Method)
FR2497746B1 (en:Method)
FR2497663B1 (en:Method)
FR2502118B3 (en:Method)
FR2500777B1 (en:Method)
FR2502332B3 (en:Method)